Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report)'s stock price fell 9.1% on Friday . The company traded as low as $5.59 and last traded at $5.68. 797,549 shares changed hands during mid-day trading, an increase of 197% from the average session volume of 268,978 shares. The stock had previously closed at $6.25.
Wall Street Analyst Weigh In
Separately, Wall Street Zen lowered shares of Dominari from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd.
Check Out Our Latest Report on DOMH
Dominari Trading Up 6.8%
The firm's fifty day moving average price is $5.01 and its 200-day moving average price is $4.33. The company has a market cap of $84.91 million, a price-to-earnings ratio of -1.29 and a beta of 0.57.
Dominari (NASDAQ:DOMH - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $0.20 earnings per share for the quarter. Dominari had a negative return on equity of 91.67% and a negative net margin of 167.73%. The firm had revenue of $6.56 million for the quarter.
Institutional Trading of Dominari
An institutional investor recently bought a new position in Dominari stock. PFG Investments LLC purchased a new stake in Dominari Holdings Inc. (NASDAQ:DOMH - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 141,508 shares of the company's stock, valued at approximately $566,000. PFG Investments LLC owned 1.30% of Dominari as of its most recent SEC filing. 42.48% of the stock is owned by institutional investors.
Dominari Company Profile
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Featured Articles
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
